LISDEXAMFETAMINE DIMESYLATE (lisdexamfetamine) by Viatris (2) is dextroamphetamine. Approved for (): • attention deficit hyperactivity disorder (adhd) in adults, a higher incidence of adverse reactions (e. First approved in 2023.
Drug data last refreshed Yesterday
dextroamphetamine. Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The exact mode of therapeutic action in ADHD and BED is not known.
Worked on LISDEXAMFETAMINE DIMESYLATE at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder
The Use of Lisdexamfetamine for Children Aged 7-13 With Attention Deficit Disorders
A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine
Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD